News

Image source: The Motley Fool.

Novartis Ag (NYSE: NVS)Q1 2024 Earnings CallApr 23, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known for its expertise in treating cystic fibrosis (CF). The biotech is the market leader, bringing in billions of dollars in revenue and profit

We have seen a stock pullback here in April, and three of these high-quality dividend paying stocks look quite intriguing. One of those stocks is healthcare company AbbVie (NYSE: ABBV) which I

Vertex Pharmaceuticals (NASDAQ: VRTX) has been through some ups and downs over the past few years. The big biotech disappointed investors when a couple of candidates outside of its specialty area of

One of the hottest themes pushing the S&P 500 and Nasdaq Composite to new heights is artificial intelligence (AI). Applications from ChatGPT and competing platforms have taken the world by storm

As investing legends like Warren Buffett probably know better than anyone, there's something satisfying about buying shares of a company you intend to hold for the rest of your career as an

In this video, I will explain why semiconductor stocks like Nvidia, Intel, ARM Holdings (NASDAQ: ARM), and Advanced Micro Devices all crashed on Friday and whether or not this presents a buying

No risk, no reward. That's a fundamental part of investing. However, some stocks are less risky than others and still offer strong growth prospects.

Three Motley Fool contributors think they've

If you're looking for dividend-paying stocks among members of the S&P 500, finding a yield high enough to inspire a purchase can be extra challenging these days. The average dividend-paying stock in

Many tech stocks recently dipped after a hotter-than-expected inflation report for March dampened hopes for brisk interest rate cuts throughout the rest of the year. The escalating conflict in the

Vertex Pharmaceuticals (NASDAQ: VRTX) is a growing pharmaceutical company with a robust cystic fibrosis (CF) business that generated nearly $10 billion in revenue last year. While there is still

If you had bought $1,000 worth of Pfizer (NYSE: PFE) shares five years ago, how much would that be worth today? The answer will strike you as terrific or terrible: $840.

That answer will be terrible

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) continues to grab headlines. Over the past six months, the drugmaker has earned important regulatory approvals and made excellent clinical

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q1 2024 Earnings CallApr 17, 2024, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its

Dividend stocks are potent instruments for building wealth. A staggering 85% of the S&P 500's total returns since 1960 have emanated from dividend payouts, according to a report by Hartford Funds.

A

Investors looking for stocks that can produce heaps of passive income want to look at recent activity from some of the world's most successful investors. Billionaire hedge fund manager Ken Griffin

Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (NASDAQ: VRTX) announced it would purchase Alpine Immune Sciences (NASDAQ: ALPN) for $4.9 billion in cash in a

Pfizer (NYSE: PFE) isn't exactly a hot stock right now. Since its massive run-up during the pandemic's height, built on hopes for its coronavirus vaccine, new sources of growth haven't led to